The latest net income for AMLX is $-150M as of June 2026. That compares with $-190M in the prior-year period — up 18.9% year over year. That is below the sector sector average of $87M. Investors often review this figure alongside Amylyx Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMLX's net income moved from $-190M to $-150M — a 18.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amylyx Pharmaceuticals's operating scale or balance-sheet position.

Against its sector companies, AMLX currently prints $-150M for net income, while the sector average sits near $87M. That is roughly 275.7% below the sector mean. Large gaps often invite a closer look at Amylyx Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $-150M for AMLX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $87M. Explore the charts below for those layers of context.

After noting AMLX's net income ($-150M), review year-over-year change from $-190M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.